Mechanism of Action
Hepatic Glucose Release
Asprosin binds to a G-protein-coupled receptor (tentatively identified as OLFR734 in mice, with a human orthologue) on hepatocytes, activating adenylate cyclase and increasing intracellular cAMP. This activates PKA, which phosphorylates and activates CREB and glycogen phosphorylase, driving rapid glycogenolysis and hepatic glucose output. The effect is acute (within minutes) and concentration-dependent, mirroring the acute glucagon response.
Hypothalamic Appetite Activation
Asprosin crosses the blood-brain barrier and acts on arcuate nucleus neurons. It activates AgRP/NPY neurons (orexigenic) and inhibits POMC neurons (anorexigenic) through a KATP channel-dependent mechanism, shifting the hypothalamic energy sensor toward hunger. This dual action amplifies food-seeking behavior in fasted states. Central asprosin levels correlate with meal initiation in mouse models.
Adipose Tissue Origin and Feedback
Asprosin is produced and secreted by white adipose tissue (WAT) in response to low insulin/glucose and sympathetic stimulation. After eating, rising insulin suppresses asprosin secretion. Body fat mass positively correlates with fasting asprosin levels, creating a paradox where obese individuals have both high asprosin (high fat mass producing more) and impaired glucose regulation. This suggests asprosin resistance or dysregulation contributes to metabolic dysfunction in obesity.
Research Summary
Obesity and Type 2 Diabetes
TranslationalHuman studies confirm asprosin is elevated in obesity, insulin resistance, PCOS, gestational diabetes, and metabolic syndrome. Anti-asprosin monoclonal antibody treatment in obese mice reduced food intake, lowered blood glucose, decreased body weight, and improved insulin sensitivity, all without affecting lean body mass. These results prompted entry into early-phase clinical trials of anti-asprosin antibodies for obesity and T2D.
Neonatal Progeroid Syndrome
Clinical (rare disease)Loss-of-function mutations in FBN1 that delete the asprosin-encoding C-terminal domain cause Neonatal Progeroid Syndrome (NPS), characterized by extreme leanness, insulin hypoglycemia, and food-seeking behavior. This rare disorder validates that asprosin is necessary for normal glucose regulation and appetite, confirming its physiological role in humans.
Cardiac and Vascular Effects
EmergingRecent studies show asprosin is elevated in heart failure patients and correlates with disease severity. In cardiomyocytes, asprosin promotes oxidative stress and inflammatory signaling. Asprosin also promotes endothelial dysfunction. These findings suggest asprosin excess in obesity may contribute to cardiovascular risk independent of its metabolic effects.
Calculate your Asprosin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Hepatic glucose assay | 10-100 nM asprosin | Single exposure (in vitro/ex vivo) | Medium supplement or IV |
| Hypothalamic appetite study | 1-5 mcg ICV | Acute single dose | ICV (animal) |
| Glucose/insulin measurement | Biomarker (blood draw) | Fasting sample | Serum ELISA |
No human therapeutic dosing established. Anti-asprosin antibodies are the therapeutic modality in development, not exogenous asprosin.
Interactions
Safety Profile
Asprosin as an exogenous therapeutic is not in clinical use. The safety profile derives from its endogenous function: excess asprosin promotes hyperglycemia, hyperphagia, and potentially cardiovascular stress. Anti-asprosin therapeutics aim to lower elevated endogenous levels. In NPS patients with absent asprosin, hypoglycemia and failure to thrive occur, establishing that physiological levels are required. For research applications, asprosin is a biomarker rather than an administered compound.
References
- [1]Romere C, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165:566-579.
- [2]Duerrschmid C, et al. Asprosin is a centrally acting orexigenic hormone. Nature Medicine. 2017.
- [3]Wang M, et al. Asprosin in metabolic and cardiovascular disease. Front Endocrinol. 2021.